Comparison of Continuous Subcutaneous Insulin Infusion and Multiple Daily Injections in Pediatric Type 1 Diabetes: A Meta‐Analysis and Prospective Cohort Study

Wang, Xu; Zhao, Xue; Chen, Danrong; Zhang, Mingzhi; Gu, Wei

doi:10.3389/fendo.2021.608232

Cited by 6 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CSII systems only use rapid‐acting insulin. In comparison with MDI, CSII therapy requires a lower insulin dosage, yields similar or superior outcomes in terms of HbA1c, and is associated with lower rates of hypoglycaemia, a similar incidence of diabetic ketoacidosis and, in most studies, also a greater treatment satisfaction 26,75‐77 …”

Section: Resultsmentioning

confidence: 99%

Rapid‐acting insulin analogues: Theory and best clinical practice in type 1 and type 2 diabetes

Block

Cauwenberghe

Bochanen

et al. 2022

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Since the discovery of insulin 100 years ago, insulin preparations have improved significantly. Starting from purified animal insulins, evolving to human insulins produced by genetically modified organisms, and ultimately to insulin analogues, all in an attempt to mimic physiological insulin action profiles seen in individuals without diabetes. Achieving strict glucose control without hypoglycaemia and preventing chronic complications of diabetes while preserving quality of life remains a challenging goal, but the advent of newer ultra-rapid-acting insulin analogues may enable intensive insulin therapy without being too disruptive to daily life. Ultra-rapid-acting insulin analogues can be administered shortly before meals and give better coverage of mealtime-induced glucose excursions than conventional insulin preparations. They also increase convenience with timing of bolus dosing. In this review, we focus on the progress that has been made in rapid-acting insulins. We summarize pharmacokinetic and pharmacodynamic data, clinical trial data supporting the use of these new formulations as part of a basal-bolus regimen and continuous subcutaneous insulin infusion, and provide a clinical perspective to help guide healthcare professionals when and for whom to use ultra-fast-acting insulins.

show abstract

Section: Resultsmentioning

confidence: 99%

Rapid‐acting insulin analogues: Theory and best clinical practice in type 1 and type 2 diabetes

Block

Cauwenberghe

Bochanen

et al. 2022

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Dies führte seit Mitte der 1990er Jahre parallel zu einer relevanten Senkung des HbA1c und gleichzeitig auch der Hypoglykämierate [13,14]. War im Jahr 1990 die konventionelle Insulintherapie (CT) auch beim Kind der Goldstandard, so änderte sich dies nach dem Jahr 1995 hin zur intensivierten Insulintherapie (ICT), bei der das Kind bzw.…”

Section: Insulinnutzung Im Zusammenhang Mit Alter Und Therapieform (C...unclassified

Entwicklung der Insulintherapie in der pädiatrischen Diabetologie- Auswertung des DPV-Registers von 1995-2021

Flury

Eckert

Datz

et al. 2023

Diabetologie und Stoffwechsel

View full text Add to dashboard Cite

ZusammenfassungDer Einsatz von Insulin zur Therapie des Diabetes mellitus Typ 1 beim Menschen hat vor 100 Jahren erstmals zum Überleben betroffener Patienten nach Manifestation der Erkrankung geführt. War zuvor die Diagnose mit der Gewissheit verknüpft, dass es sich um eine unmittelbar lebensbedrohliche Erkrankung handelt, wurde mit dem Einsatz des Hormons Insulin ab 1922 die Perspektive eröffnet, den Verlauf der Erkrankung zu beeinflussen und die Prognose für die Patienten damit zu verbessern.Ziel der vorliegenden Arbeit ist die Analyse von 92366 Patienten eines pädiatrischen Patientenkollektivs aus Deutschland, Österreich, Luxemburg und der Schweiz im Hinblick auf den Einsatz der verschiedenen Insulinarten im Zeitraum 1995–2021.Der Anteil der Insulinanaloga stieg insbesondere seit dem Jahr 2000 stark an, auch da die Nutzung von Insulinpumpen mit Analoginsulin im Vergleich zur intensivierten Insulintherapie mit Pen für alle Altersgruppen deutlich anstieg. Bereits im Jahr 2010 betrug der Anteil der Insulinanaloga in der Diabetestherapie bei Kindern insgesamt > 60 %.Im Jahr 2022 können Diabetologen auf mehr als zehn Insulinarten und mindestens fünf verschiedene Therapieformen zur Behandlung des Diabetes mellitus Typ 1 zurückgreifen.

show abstract

“…ППИИ связана с лучшим гликемическим контролем и лучшим эффектом для развития роста детей. Применение ППИИ не влияет на сроки и темпы полового развития, однако в значительной мере снижает риски развития долгосрочных осложнений [4].…”

Section: Introductionunclassified

Glycemic control parameters in children with type 1 diabetes treated with fast-acting insulin aspart domestic biosimilar by continuous subcutaneous infusion

Platonov,

Dubinina,

Patrakeeva

et al. 2023

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. Type 1 diabetes (T1D) is a chronic autoimmune disease requiring constant insulin therapy under regular continuous monitoring of glycemic parameters. The use of domestic insulin bioanalogues in CSII therapy is currently not sufficiently covered in the literature.Aim. To evaluate glycemic control parameters in children with T1D treated with the domestic fast-acting insulin aspart biosimilar by CSII.Materials and methods. Retrospective study was carried out on the basis of K.A. Raukhfus center St. Petersburg State Medical and Biomedical Center VMT. Fifty-five children with T1D aged 6 to 17 years (mean age 12 ± 4) were examined, including 29 boys (52.7%, mean age 11 ± 3 years) and 26 girls (47.3%, mean age 13 ± 4 years). Insulin therapy was carried out by systems of CSII Glycemic parameters were monitored by continuous and flash glycemic monitoring systems. The center visits frequency was once a month.Results. During dynamic follow-up after 3 and 6 months, children showed statistically significant (p < 0.05) improvement in glycemic control parameters–decrease in HbA1c level from 8.0 ± 1.8% to 7, 1 ± 1.2% and 6.8 ± 0.6%, increase in TIR from 60.4 ± 20.6% to 71.5 ± 13.0% and 75.9 ± 9.4%, decrease in TAR from 31.1 ± 22.1% to 23.0 ± 12.8% and 20.3 ± 9.3%, decrease in TBR from 9.1 ± 8.2% to 5.8 ± 4.3% and 4.1 ± 1.8%, and decrease in CV from 40.0 ± 9.1% to 33.7 ± 6.7% and 32.5 ± 5.6%.Discussion. The use of domestic biosimilar insulin aspart in insulin pumps iis associated with significant improvement in glycemic control in children and adolescents with T1D. Dynamic observation together with therapeutic education contribute to the maintenance of the achieved parameters at a high level.Conclusions. Therapy with the domestic fast-acting insulin aspart biosimilar by CSII allows achieving target glycemic control in children with T1D.

show abstract

Comparison of Continuous Subcutaneous Insulin Infusion and Multiple Daily Injections in Pediatric Type 1 Diabetes: A Meta‐Analysis and Prospective Cohort Study

Cited by 6 publications

References 31 publications

Rapid‐acting insulin analogues: Theory and best clinical practice in type 1 and type 2 diabetes

Rapid‐acting insulin analogues: Theory and best clinical practice in type 1 and type 2 diabetes

Entwicklung der Insulintherapie in der pädiatrischen Diabetologie- Auswertung des DPV-Registers von 1995-2021

Glycemic control parameters in children with type 1 diabetes treated with fast-acting insulin aspart domestic biosimilar by continuous subcutaneous infusion

Contact Info

Product

Resources

About